



Biotech Daily

Thursday July 15, 2021

Daily news on ASX-listed biotechnology companies

Actinogen Enrols 1st Xanamia Trial Patient

[ACTINOGEN MEDICAL](#)

Actinogen says the first of 105 older healthy volunteers have been enrolled in part A of its two-part trial of Xanamem for mild cognitive impairment due to Alzheimer's disease.

Actinogen said part A of the 'Xanamia' trial would be conducted over six weeks at four outpatient sites in Australia and would use the Cogstate neurological test battery, including the digit symbol substitution test, which was an US Food and Drug Administration-approved endpoint for cognition.

The company said that the dose-ranging part A would assess the efficacy of 5mg and 10mg doses of Xanamem in patients with biomarker-positive Alzheimer's disease and part B would measure the effects of Xanamem on biomarkers of the disease and on cognition.

Actinogen was unchanged at 11.5 cents with 16.2 million shares traded.